A new PwC report says the women’s oncology market could reach $110 billion by 2030, though funding and care gaps remain. The post Women’s Oncology Market Could Reach $110B in 2030, but Gaps Remain appeared first on MedCity News.
Merck’s Lipfendra is the first FDA-approved pill in the class of cholesterol-lowering drugs called PCSK9 inhibitors. While peptides are typically injected, Lipfendra is a macrocyclic peptide designed for formulation as an oral drug. The post Merck Pill Becomes First Oral Option in Growing Class of Cholesterol-Lowering Drugs appeared first on MedCity News.
What should life sciences investors and targets focus on for dealmaking success? Here are six actionable steps. The post Hybrid Financing in Life Sciences: Unlocking Growth Amid Market Challenges appeared first on MedCity News.
Here’s what healthcare entities should know about the maturing landscape, what to actually be concerned about, and the next stage of healthcare data evolution as we know it. The post Are We Entering an Interoperability Trust Recession? appeared first on MedCity News.
Céline Gounder, KFF Health News’ editor-at-large for public health, discussed the Department of Health and Human Services’ plan to offer compensation for automatic covid vaccine injuries and the drop in enrollment in Affordable Care Act health plans on CBS’ The Takeout With Major Garrett on July 10 and 9, respectively. Click here to watch Gounder…
Juno Bio’s funding was supported by Ada Ventures, Artesian, Entrepreneur First and Illumina Accelerator. The post Juno Bio Raises $3.8M to Support Vaginal Health appeared first on MedCity News.
HSS chief digital and information officer Ashis Barad, who has worked on both the payer and provider sides of healthcare AI, thinks the industry’s growing “bot vs. bot” battle over prior authorizations and appeals is driving costs up. To him, the real fix lies in providers and payers sharing data to build more personalized care…
Leaders emphasize collaboration and understanding system interdependencies
Leaders of the parent of Anthem and Wellpoint recently agreed with D.C. officials to leave that jurisdiction and say they are focused on long-term financial sustainability.
GSK said the mixed Phase 3 results for camlipixant mean this pill “is unlikely to transform patient care” in recurrent chronic cough. GSK is stopping work in this indication, a setback to a program once hoped to yield a new blockbuster product for the company’s respiratory drug portfolio. The post GSK Drug From $2B Deal…